← All Pharvaris NV filings

Pharvaris NV Schedule 13G passive stakes

Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.

NASDAQ
PHVS
Pharvaris NV
SCHEDULE: General Atlantic Adjusts Pharvaris Stake to 7.6%
General Atlantic entities have collectively adjusted their beneficial ownership of Pharvaris N.V. ordinary shares to 7.6%, as reported in an amended Schedule 13G filing.
NASDAQ
PHVS
Pharvaris NV
SCHEDULE: Pharvaris N.V. Shareholding Update by LSP V
LSP V Cooperatieve U.A. and LSP V Management B.V. report a 4.9% stake in Pharvaris N.V. as of June 30, 2026.
NASDAQ
PHVS
Pharvaris NV
SCHEDULE: Viking Global Updates Ownership Stake in Pharvaris N.V.
Viking Global Investors LP filed an amendment to its Schedule 13G, reporting a 5.6% beneficial ownership stake in Pharvaris N.V. following the retirement of David C. Ott.
NASDAQ
PHVS
Pharvaris NV
SCHEDULE: Bain Capital Life Sciences Discloses 5.1% Stake in Pharvaris N.V.
Bain Capital Life Sciences entities have disclosed a collective beneficial ownership of 5.1% in Pharvaris N.V., totaling 3,181,275 ordinary shares as of September 30, 2025.
NASDAQ
PHVS
Pharvaris NV
SCHEDULE: Venrock Group Cuts Pharvaris Stake to 3.8%
A group of investors led by Venrock Healthcare Capital Partners has reduced its beneficial ownership in Pharvaris N.V. to 3.8% of ordinary shares.